Ignite Creation Date:
2024-05-05 @ 11:34 AM
Last Modification Date:
2024-10-26 @ 9:10 AM
Study NCT ID:
NCT00080340
Status:
COMPLETED
Last Update Posted:
2008-01-15
First Post:
2004-03-26
Brief Title:
Study of TLK286 Telcyta vs Gefitinib in Locally Advanced or Metastatic Non-Small Cell Lung Cancer
Sponsor:
Telik
Organization:
Telik
Study Overview
Official Title:
Phase 3 Randomized Study of TLK286 Telcyta Versus Gefitinib Iressa as Third-Line Therapy in Locally Advanced or Metastatic Non-Small Cell Lung Cancer
Status:
COMPLETED
Status Verified Date:
2006-03
Last Known Status:
None
Delayed Posting:
No
If Stopped, Why?:
Not Stopped
Has Expanded Access:
No
If Expanded Access, NCT#:
N/A
Has Expanded Access, NCT# Status:
N/A
Acronym:
None
Brief Summary:
The purpose of this study is to determine if TLK286Telcyta is more effective than gefitinib Iressa in the treatment of non-small cell lung cancer
Detailed Description:
None
Study Oversight
Has Oversight DMC:
None
Is a FDA Regulated Drug?:
None
Is a FDA Regulated Device?:
None
Is an Unapproved Device?:
None
Is a PPSD?:
None
Is a US Export?:
None
Is an FDA AA801 Violation?:
None